Remove 2028 Remove Clinical Development Remove Pharmaceuticals Remove Pharmacokinetics
article thumbnail

Pfizer Investor Day Features Significant Number of Pipeline Advances for COVID-19 Programs and Across Numerous Therapeutic Areas

The Pharma Data

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. UPDATES ON COVID-19 DEVELOPMENT PROGRAMS. The company announced the initiation of its Phase 1b clinical trial to evaluate the safety of a novel investigational therapeutic for COVID-19, PF-07304814.

Vaccine 52